(Q46513852)

22 December 2017

title

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity (English)

1 reference

22 December 2017

0 references

1 reference

Creutzig U

1

1 reference

22 December 2017

Reinhardt D

2

1 reference

22 December 2017

Diekamp S

3

1 reference

22 December 2017

Dworzak M

4

1 reference

22 December 2017

Stary J

5

1 reference

22 December 2017

Zimmermann M

6

1 reference

22 December 2017

publication date

1 August 2005

1 reference

22 December 2017

published in

Leukemia

1 reference

22 December 2017

volume

19

1 reference

22 December 2017

issue

8

1 reference

22 December 2017

page(s)

1355-1360

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403814

exact match

0 references

cites work

Down syndrome and acute leukemia in children: A 10-year retrospective survey from Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Megakaryoblastic leukemia and Down's syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Improved outcome of acute myeloid leukaemia in Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Onco

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

[Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

[Acute myeloid leukemia in children with Down syndrome]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Acute leukaemia in children with Down syndrome: a population-based Nordic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403814

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403814

1 reference

22 December 2017

1 reference

22 December 2017